BiotechTube
Home/Pipeline/Lecanemab

Lecanemab

Alzheimer's Disease

LaunchedActive (Commercial)

Key Facts

Indication
Alzheimer's Disease
Phase
Launched
Status
Active (Commercial)
Company
BioArctic

About BioArctic

BioArctic is a research-driven biopharma company with a mission to develop transformative treatments for neurodegenerative diseases. Its strategic partnership with Eisai led to the landmark approval and commercialization of lecanemab for Alzheimer's, providing a foundational revenue stream. The company's core strategy is to leverage its proprietary BrainTransporter™ platform to build a diversified pipeline of next-generation biologics for Parkinson's and ALS, while continuing to advance its Alzheimer's franchise.

View full company profile

Therapeutic Areas

Alzheimer's DiseaseParkinson's DiseaseALS

Other Alzheimer's Disease Drugs

DrugCompanyPhase
ALZN002Alzamend NeuroPreclinical
P021Phanes BiotechPreclinical
PB43DPhanes BiotechPreclinical
UB-311VaxxinityPhase 2
BAN2401BioArcticPreclinical
itMSCsStemedica Cell TechnologiesClinical Development
Aucuba-001Aucuba SciencesPreclinical
ALTA Drug SeriesAlteron TherapeuticsPreclinical
NTRX-07NeuroTherapiaPhase 2
3D Neuronal Disease ModelsBioTalentumResearch
Not Publicly DisclosedCerecinPhase 1/2
Not SpecifiedAsceneuronNot Disclosed